English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16984/19280 (88%)
Visitors : 8583829      Online Users : 727
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32225


    標題: High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy
    作者: Chen, Tzu-Ju
    He, Hong-Lin
    Shiue, Yow-Ling
    Yang, Ching-Chieh
    Lin, Li-Ching
    Tian, Yu-Feng
    Chen, Shang-Hung
    貢獻者: Chi Mei Med Ctr, Dept Pathol
    Chung Hwa Univ Med Technol, Dept Optometry
    Natl Sun Yat Sen Univ, Inst Biomed Sci
    Chi Mei Med Ctr, Dept Radiat Oncol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chi Mei Med Ctr, Dept Surg, Div Gen Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Natl Hlth Res Inst, Natl Inst Canc Res
    Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med
    關鍵字: CLCA1
    rectal cancer
    concurrent chemoradiotherapy
    日期: 2018
    上傳時間: 2019-11-15 15:45:50 (UTC+8)
    出版者: IVYSPRING INT PUBL
    摘要: Background: Concurrent chemoradiotherapy (CCRT) has now become the standard of treatments for advanced rectal cancer before surgery. To search the biological molecules with prognostic and therapeutic potential of CCRT could be beneficial for these patients. Recently, aberrant expression of chloride channels has been linked to radio-resistance in glioblastoma; however, its clinical implication has not been well-studied in rectal cancers. Therefore, we examined the clinical significance of targetable drivers associated with chloride channel activity in patients with rectal cancer receiving CCRT. Methods: After datamining from a published transcriptome of rectal cancers, upregulation of CLCA1 gene was recognized to be significantly correlated with non-responders of CCRT. In validation cohort of rectal cancers, the expression levels of CLCA1 were accessed by using immunohistochemistry assays in 172 tumor specimens that were obtained before any treatment. Expression levels of CLCA1 were statistically analyzed with principal clinicopathological features and survival outcomes in this substantial cohort. Results: In validation cohort, high expression of CLCA1 was significantly associated with higher pre-treatment tumor nodal stages (P=0.032), vascular invasion (P=0.028), and inferior tumor regression grade (P=0.042). In survival evaluations, high expression of CLCA1 was significantly correlated with worse local recurrence-free survival (LRFS; P=0.0012), metastasis-free survival (MeFS; P =0.0114), and disease-specific survival (DSS; P=0.0041). Furthermore, high expression of CLCA1 remained an independent prognosticator of shorter LRFS (P=0.029, hazard ratio=2.555), MeFS (P=0.044, hazard ratio=2.125) and DSS (P=0.044, hazard ratio=2.172). Conclusions: High expression of CLCA1 is significantly associated with poor therapeutic response and survival outcomes in rectal cancer patients with CCRT treatment before surgery. With the development of specific inhibitors, our findings indicate not only prognostic but also therapeutic potential of CLCA1 in rectal cancers.
    link: http://dx.doi.org/10.7150/ijms.26685
    Appears in Collections:[藥學系(所)] 期刊論文
    [保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.7150-ijms.26685.pdf873KbAdobe PDF5View/Open
    index.html0KbHTML18View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback